Videos

Learn how early antidepressant response guides faster treatment changes in major depression, with earlier use of esketamine, TMS, and ECT despite insurance barriers.

Learn how experts distinguish agitation from psychosis in Alzheimer disease, weigh new FDA options, and apply evidence for off-label care.

A student advocate focuses on policy, pushing campus naloxone, overdose training, and early prevention to curb South Carolina’s opioid deaths.

Low-dose TNX-102 SL targets sleep receptors for MDD, avoiding norcyclobenzaprine buildup and promising cleaner daytime tolerability in HORIZON trial.

Explore how TNX-102 SL aims to improve major depressive disorder by enhancing slow-wave sleep, as the HORIZON phase 2 trial tests nightly dosing.

Consensus definition clarifies Alzheimer agitation, reviews FDA-approved brexpiprazole and dextromethorphan-bupropion, and spotlights caregiver burden

How clinicians can provide stronger care for minority groups and have a culturally informed practice.

Fatigue and poor sleep send patients to primary care, but a CBC and a thyroid panel will not find depression. The panel examines what actually separates major depression from its mimics.

Clinicians outline ways to boost schizophrenia outcomes: team-and-family collaboration, early detection, medication access, measurement-based care.

New rapid-acting and long-acting injectables help bridge hospital-to-community care, cutting post-discharge nonadherence and relapse risk.

Depression rarely arrives named. The panel opens on the presentations that mask it, the risk factors worth flagging in primary care, and the lag between first symptom and adequate treatment.

Explore next-gen depression therapies targeting neuroplasticity and why biomarkers may unlock precision psychiatry for MDD.

How Austedo’s VMAT2 inhibition reshapes tardive dyskinesia care, while real-world data reveal underdiagnosis, low uptake, and new studies ahead.

Experts unpack placebo and nocebo effects in psychiatry, revealing how expectation, framing, and alliance boost outcomes and curb side effects.

Three new Teva posters show Austedo sustains tardive dyskinesia improvement long term, works in real-world care, and education boosts diagnosis and visits.

Clinicians weigh telepsychiatry for schizophrenia, urge early long-acting injectables, and reveal tips on samples, coupons, and prior authorizations.

Inside the ED psychiatric crisis pathway: rapid evaluation, safety triage, long-acting injectables,

Discover how coordinated schizophrenia care teams—clinicians, social supports, and peers—improve communication, housing, work, and quality of life.

Where can vagus nerve stimulation fit into treating depression?

Clinicians track relapse risk in schizophrenia by spotting functional decline, paranoia, missed care, and triggers, using family check-ins, brief scales, and labs.

Motivational interviewing can help psychiatrists address long-acting injectable hesitancy in schizophrenia, according to Gerald Maguire, MD.

Phase 3 COMP360 psilocybin data show lasting TRD relief; experts explain brain-network reset, therapy support, and what approval could mean.

Why sleep checks matter in ADHD: spot apnea, executive dysfunction, and hidden ADHD behind treatment-resistant depression.

Learn about screening for postpartum depression and available pharmacological treatments.

Gerald A. Maguire, MD, shares his experience and insights on the importance of trust and empathy.

Explore newly FDA-approved ADHD treatments and late-stage contenders, plus practical guidance on managing sleep disorders with evidence-based behavioral strategies.

Explore rapid TRD breakthroughs: accelerated TMS like SAINT, emerging neuromodulation tools, near-term psychedelic therapies, and why sharper diagnosis improves outcomes.

Consensus guidance clarifies IV ketamine dosing, monitoring, staffing and consent to support safer, evidence-based depression treatment.

Experts urge metabolic screening across psychiatric diagnoses, spotlighting tailored interventions and tools like PsyMetRiC—while warning risk talks can backfire.

New Delphi consensus guides off-label IV ketamine for depression, detailing protocols and rapid antisuicidal mechanisms via neuroplasticity and BDNF.